3 results match your criteria: "Eastern Virginia Medical School Urology of Virginia[Affiliation]"
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Prostate Cancer Prostatic Dis
September 2020
University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Purpose: African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and Caucasian men receiving sipuleucel-T. We explored this in PROCEED (NCT01306890), an FDA-requested registry in over 1900 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T.
View Article and Find Full Text PDFA Urologist's Personal View of Prostate Cancer.
Turk J Urol
September 2016
Department of Urology, Eastern Virginia Medical School Urology of Virginia, USA.
A urologist's personal experience with multiple surgical, hormonal, and radio/immunotherapeutic options for the treatment of advanced prostate cancer and thoughts on the role of old and new therapies.
View Article and Find Full Text PDFA Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
September 2015
Carolina Urologic Research Center, Myrtle Beach, South Carolina.
Purpose: This phase II open-label study evaluated the effect of concurrent or sequential administration of abiraterone acetate plus prednisone (AA + P) on sipuleucel-T manufacture and immune responses in metastatic castration-resistant prostate cancer (mCRPC) patients.
Experimental Design: mCRPC patients received sipuleucel-T followed by AA + P 1 day (concurrent) or 10 weeks (sequential) after the first sipuleucel-T infusion. AA + P treatment continued for 26 weeks.